Vertex Energy files restructuring plan after filing for bankruptcy
In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Beyond The Numbers: 12 Analysts Discuss Vertex Stock
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...
Hosted on MSN19h
DA Davidson Initiates Coverage of Vertex (VERX) with Buy Recommendation
Fintel reports that on December 31, 2024, DA Davidson initiated coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.
Vertex Poised for Growth: Strategic Acquisitions and Market Positioning Drive Buy Rating
Vertex (VERX) has received a new Buy rating, initiated by D.A. Davidson analyst, Will Jellison.Don't Miss Our New Year's Offers:Discover the ...
Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?
Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...
Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's fourth consecutive day of gains.
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...
Zacks.com on MSN15h
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...